Abstract
The effect of estramustine phosphate (Estracyt) on the growth of murine aplastic mammary carcinoma, Ehrlich carcinoma, melanoma B-16, and five cell lines: L929 (mouse fibroblasts), BHK (baby hamster kidney), HeLa (human cervical carcinoma), HEp-2 (human laryngeal carcinoma), and K562 (human granulocytic leukemia) was investigated. In vivo, estramustine phosphate inhibits the growth of aplastic mammary carcinoma and Ehrlich carcinoma, but has no effect on melanoma B-16. In cultured aplastic mammary carcinoma, estramustine phosphate decreased the incorporation of 3H-thymidine into DNA. This drug inhibits the population growth of L929, BHK, HEp-2, and K562 cultures, but stimulates the growth of HeLa cells. We conclude that estramustine phosphate retards the growth of various cells, and that studies of other potential fields of application of the drug (aside from prostatic carcinoma) is justified.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.